Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel H Solomon

Showing results (311-320 of 524) with videos related to

Pageof 53
Sort By:
Journal of Clinical & Cellular Immunology|March 28, 2014
Erythropoiesis-stimulating Agent Use among Patients with Lupus Nephritis Approaching End-stage Renal DiseaseJosé A Gómez-Puerta, Sushrut S Waikar, Daniel H Solomon, et al.
The American Journal of Managed Care|July 11, 2009
Measuring concurrent adherence to multiple related medicationsNiteesh K Choudhry, William H Shrank, Raisa L Levin, et al.
Pharmacoepidemiology and Drug Safety|December 29, 2016
The clinical status and economic savings associated with remission among patients with rheumatoid arthritis: leveraging linked registry and claims data for synergistic insightsJeffrey R Curtis, Lang Chen, Jeffrey D Greenberg, et al.
Arthritis Care & Research|January 29, 2014
Predictors of stopping and starting disease-modifying antirheumatic drugs for rheumatoid arthritisDaniel H Solomon, Chris Tonner, Bing Lu, et al.
Annals of the Rheumatic Diseases|December 4, 2013
The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factorLeslie R Harrold, George W Reed, Joel M Kremer, et al.
Rheumatology (Oxford, England)|June 18, 2021
Adverse effects related to methotrexate polyglutamate levels: adjudicated results from the cardiovascular inflammation reduction trialChang Xu, Jacob Selhub, Paul Jacques, et al.
The Journal of Clinical Endocrinology and Metabolism|January 3, 2020
Delayed Denosumab Injections and Bone Mineral Density Response: An Electronic Health Record-based StudyHouchen Lyu, Sizheng S Zhao, Kazuki Yoshida, et al.
Seminars in Arthritis and Rheumatism|November 10, 2021
Risk of venous thromboembolism associated with methotrexate versus hydroxychloroquine for rheumatoid arthritis: A propensity score-matched cohort studyMengdong He, Ajinkya Pawar, Rishi J Desai, et al.
The Journal of Clinical Endocrinology and Metabolism|July 3, 2019
Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate UseHouchen Lyu, Sizheng S Zhao, Kazuki Yoshida, et al.
Journal of the American Heart Association|February 28, 2024
Biomarkers of Cardiovascular Risk in Patients With Rheumatoid Arthritis: Results From the TARGET TrialDaniel H Solomon, Olga Demler, Pamela M Rist, et al.
Pageof 53

Showing results (311-320 of 524) with videos related to

Sort By:
Pageof 53
Journal of Clinical & Cellular Immunology|March 28, 2014
Erythropoiesis-stimulating Agent Use among Patients with Lupus Nephritis Approaching End-stage Renal DiseaseJosé A Gómez-Puerta, Sushrut S Waikar, Daniel H Solomon, et al.
The American Journal of Managed Care|July 11, 2009
Measuring concurrent adherence to multiple related medicationsNiteesh K Choudhry, William H Shrank, Raisa L Levin, et al.
Pharmacoepidemiology and Drug Safety|December 29, 2016
The clinical status and economic savings associated with remission among patients with rheumatoid arthritis: leveraging linked registry and claims data for synergistic insightsJeffrey R Curtis, Lang Chen, Jeffrey D Greenberg, et al.
Arthritis Care & Research|January 29, 2014
Predictors of stopping and starting disease-modifying antirheumatic drugs for rheumatoid arthritisDaniel H Solomon, Chris Tonner, Bing Lu, et al.
Annals of the Rheumatic Diseases|December 4, 2013
The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factorLeslie R Harrold, George W Reed, Joel M Kremer, et al.
Rheumatology (Oxford, England)|June 18, 2021
Adverse effects related to methotrexate polyglutamate levels: adjudicated results from the cardiovascular inflammation reduction trialChang Xu, Jacob Selhub, Paul Jacques, et al.
The Journal of Clinical Endocrinology and Metabolism|January 3, 2020
Delayed Denosumab Injections and Bone Mineral Density Response: An Electronic Health Record-based StudyHouchen Lyu, Sizheng S Zhao, Kazuki Yoshida, et al.
Seminars in Arthritis and Rheumatism|November 10, 2021
Risk of venous thromboembolism associated with methotrexate versus hydroxychloroquine for rheumatoid arthritis: A propensity score-matched cohort studyMengdong He, Ajinkya Pawar, Rishi J Desai, et al.
The Journal of Clinical Endocrinology and Metabolism|July 3, 2019
Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate UseHouchen Lyu, Sizheng S Zhao, Kazuki Yoshida, et al.
Journal of the American Heart Association|February 28, 2024
Biomarkers of Cardiovascular Risk in Patients With Rheumatoid Arthritis: Results From the TARGET TrialDaniel H Solomon, Olga Demler, Pamela M Rist, et al.
Pageof 53